Skip to search formSkip to main contentSkip to account menu

Tafinlar

National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

dabrafenibdabrafenib mesylate
dabrafenib 75 MG Oral Capsule [Tafinlar]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Targeted therapy for the adjuvant treatment of stage III BRAF-mutated melanoma.
GL We undertook the COMBI-AD study (Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma) because the COMBI-v… 
Review
2018
Review
2018
Dabrafenib/Trametinib Granted Priority Review for Stage III BRAF-Mutated Melanoma
The FDA has granted priority review to the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) for the adjuvant… 
2018
2018
Does adjuvant therapy for high-risk melanoma with either immunotherapy or targeted therapy affect therapeutic choices at relapse?
MP The drugs that have received approval from the US Food and Drug Administration (FDA) for this use are interferon alfa-2b… 
2016
2016
Is there a role for single-agent MEK inhibition in melanoma?
DJ The US Food and Drug Administration has approved 2 MEK inhibitors for use in advanced BRAF V600mutant melanoma: trametinib… 
2015
2015
[Dabrafenib (Tafinlar) therapy - effect and side effects].
Despite the continuously increasing incidence of melanoma, over decades the therapy has barely changed. However, since 2011 the… 
Review
2015
Review
2015
Molecular approaches to tumor inhibition in melanoma.
MD The US Food Administration (FDA) has approved several molecularly targeted agents for use in patients with metastatic melanoma… 
2013
2013
Dabrafenib, trametinib: Single-agent drugs for advanced melanoma
2013
2013
Dabrafenib (Tafinlar) and trametinib (Mekinist) metastatic melanoma.
2013
2013
NEW FORMULATIONS A Higher Lipase Dose for Creon
  • 2013
  • Corpus ID: 23376239
Menkinist and Tafinlar For Melanoma Two drugs made by GlaxoSmithKline—dabrafenib (Tafinlar) and trametinib (Mekinist)—have been… 
2013
2013
Tafinlar and Mekinist: Two Oral Targeted Kinase Inhibitors for the Treatment of Patients with Metastatic Melanoma and BRAF Mutations
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)